Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases
- 1Cardiff University
Abstract
Neurodegenerative diseases (NDDs) are driven by multiple related yet distinct pathological processes that evolve over decades, resulting in substantial clinical and neuropathological heterogeneity. Postmortem examinations of older individuals frequently reveal multiple coexisting neuropathologies, however, the underlying pathological processes cannot be easily assessed directly in living individuals. To quantify pathology-specific genetic signatures, we analysed a spectrum of NDDs using polygenic risk scores (PRSs) in the UK Biobank, restricting analyses to genes reported to be expressed in major brain cell-types, including microglia, astrocytes, oligodendrocytes, and neurons. We found substantial overlap among purportedly cell-type specific gene sets (21-29%), with APOE or neighbouring genes from the APOE locus represented in all gene sets, indicating that current cell-type specific annotations capture considerable shared genetic variation across cell-types. Jointly, cell-type specific PRSs explained a large proportion (60-93%) of the genetic liability for NDDs in which dementia is a major clinical manifestation. Alzheimers disease (AD) showed associations across all cell-types, with oligodendrocyte- and astrocyte-based PRSs demonstrating strong effects independent of APOE. AD PRS and APOE status independently differentiated Parkinsons disease (PD) with dementia from PD without dementia. PD without dementia and amyotrophic lateral sclerosis (ALS) exhibited distinct genetic profiles, with limited overlap with other NDDs. Collectively, these findings reveal both shared and disease-specific genetic contributions across neurodegenerative disorders and demonstrate that currently available cell-type specific gene sets capture substantial overlapping genetic risk. The imperfect alignment between clinical phenotypes and underlying pathology, coupled with the extensive overlap of gene expression across these cell types, underscores the persistent challenges in resolving the genetic architecture of neurodegenerative diseases and elucidating their underlying biological mechanisms.
Related
- Targeting Ferroptosis in Neurodegenerative Diseases: Therapeutic Potential and Mechanistic Insights of Traditional Chinese Medicine.
- Brain aging and neurodegenerative diseases: physiological insights from anti-aging protein Klotho
- Hybrid risk scores integrating polygenic and clinical variables for endometriosis prediction
- Adult Patient Perspectives on Psychiatric Polygenic Risk Scores
- Polygenic risk scores for LATE-neuropathologic change: Implications for clinical utility.
BibTeX
@misc{simmonds2026mapping,
title = {{Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases}},
author = {E. Simmonds and A. McKeever and U. Yaman and G. Leonenko and K. Kimatova and P. Taylor and S. Chandran and M. Ryten and B. Khakh and J. T. O'Brien and T. Spires-Jones and D. A. Salih and V. Escott-Price},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.08.26365054},
url = {https://www.medrxiv.org/content/10.64898/2026.10.08.26365054v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Mapping polygenic risk scores to brain cells: insights for neurodegenerative diseases
AU - E. Simmonds
AU - A. McKeever
AU - U. Yaman
AU - G. Leonenko
AU - K. Kimatova
AU - P. Taylor
AU - S. Chandran
AU - M. Ryten
AU - B. Khakh
AU - J. T. O'Brien
AU - T. Spires-Jones
AU - D. A. Salih
AU - V. Escott-Price
PY - 2026
DA - 2026/10/08
PB - medRxiv
DO - 10.64898/2026.10.08.26365054
UR - https://www.medrxiv.org/content/10.64898/2026.10.08.26365054v1
AB - Neurodegenerative diseases (NDDs) are driven by multiple related yet distinct pathological processes that evolve over decades, resulting in substantial clinical and neuropathological heterogeneity. Postmortem examinations of older individuals frequently reveal multiple coexisting neuropathologies, however, the underlying pathological processes cannot be easily assessed directly in living individuals. To quantify pathology-specific genetic signatures, we analysed a spectrum of NDDs using polygenic risk scores (PRSs) in the UK Biobank, restricting analyses to genes reported to be expressed in major brain cell-types, including microglia, astrocytes, oligodendrocytes, and neurons. We found substantial overlap among purportedly cell-type specific gene sets (21-29%), with APOE or neighbouring genes from the APOE locus represented in all gene sets, indicating that current cell-type specific annotations capture considerable shared genetic variation across cell-types. Jointly, cell-type specific PRSs explained a large proportion (60-93%) of the genetic liability for NDDs in which dementia is a major clinical manifestation. Alzheimers disease (AD) showed associations across all cell-types, with oligodendrocyte- and astrocyte-based PRSs demonstrating strong effects independent of APOE. AD PRS and APOE status independently differentiated Parkinsons disease (PD) with dementia from PD without dementia. PD without dementia and amyotrophic lateral sclerosis (ALS) exhibited distinct genetic profiles, with limited overlap with other NDDs. Collectively, these findings reveal both shared and disease-specific genetic contributions across neurodegenerative disorders and demonstrate that currently available cell-type specific gene sets capture substantial overlapping genetic risk. The imperfect alignment between clinical phenotypes and underlying pathology, coupled with the extensive overlap of gene expression across these cell types, underscores the persistent challenges in resolving the genetic architecture of neurodegenerative diseases and elucidating their underlying biological mechanisms.
ER -